US Patent 8,883,849: Claim Scope, Exclusivity, Litigation Risk, and Patent Landscape for Ibuprofen-Diphenhydramine Softgels

US Patent 8,883,849 protects a treatment method using a liquid-filled soft gelatin capsule containing ibuprofen, diphenhydramine, polyethylene glycol, potassium hydroxide, and water. Its principal commercial read-through is an Advil PM-type product containing 200 mg ibuprofen and 38 mg diphenhydramine citrate. The patent does not broadly claim every ibuprofen-diphenhydramine product. It requires a specific dosage form, solvent system, ingredient combination, and treatment purpose.

The strongest infringement position is against a product that administers the claimed composition in a softgel to treat pain-associated sleep disturbance. A tablet, caplet, dry powder, or composition using a materially different excipient system would not fall within the literal scope of the independent claims.

What does US Patent 8,883,849 protect?

US Patent 8,883,849, titled “Treatment of Pain-Associated Sleep Disturbance,” is a method-of-treatment patent. The patent claims administering a liquid composition inside a soft gelatin capsule to a patient with pain-associated sleep disturbance. The composition contains:

Required element	Claim requirement
Ibuprofen	About 200-400 mg in claim 1; 200-400 mg in claim 15
Diphenhydramine	About 10-50 mg in claim 1; about 12.5-50 mg in claim 15
Salt form	Diphenhydramine hydrochloride or diphenhydramine citrate in dependent claims
Vehicle	Polyethylene glycol, potassium hydroxide, and water
Physical form	Liquid composition formulated inside a soft gelatin capsule
Use	Treatment of pain-associated sleep disturbance
Dosing	One dose, two doses, or one dose with an optional second dose

The patent is narrower than a composition patent because infringement requires practice of the claimed treatment method. The patent is also narrower than a broad combination-drug patent because the claims require both the liquid softgel dosage form and the specified excipient system.

How are the independent claims structured?

Claim 1

Claim 1 is the broader independent claim for the first claim set. It requires:

A patient suffering from pain-associated sleep disturbance.
Administration of a liquid composition.
The liquid composition is formulated inside a soft gelatin capsule.
The composition consists of:
- about 200-400 mg ibuprofen;
- about 10-50 mg diphenhydramine;
- polyethylene glycol;
- potassium hydroxide; and
- water.

The phrase “consists of” is important. It generally operates as a closed transition, excluding additional unrecited ingredients that materially change the claimed composition. In practice, ordinary minor components, manufacturing residues, capsule-shell materials, or ingredients that do not alter the basic and novel characteristics may not automatically avoid infringement. The precise result would depend on claim construction and the prosecution history.

Claim 15

Claim 15 is a second independent claim with a narrower diphenhydramine range. It requires about 12.5-50 mg diphenhydramine rather than the broader 10-50 mg range in claim 1.

The overlap between claims 1 and 15 is substantial. A product containing 200 mg ibuprofen and 25 mg diphenhydramine hydrochloride falls within both independent claims if the other elements are satisfied. A product containing 200 mg ibuprofen and 10 mg diphenhydramine may fall within claim 1 but not claim 15.

Which commercial formulations most directly map to the patent?

The closest commercial configuration is a liquid-filled softgel containing 200 mg ibuprofen and 38 mg diphenhydramine citrate. This corresponds to the specific alternatives in claims 8, 9, 16, and 18-19.

Commercially relevant formulation	Claim mapping
200 mg ibuprofen + 38 mg diphenhydramine citrate softgel	Claims 1, 8-9, 15-16, 18-19
200 mg ibuprofen + 25 mg diphenhydramine HCl softgel	Claims 1, 5-7, 10-11, 15-17, 19
300 mg ibuprofen + 25 mg diphenhydramine HCl softgel	Claims 1, 5-6, 10, 15-17
400 mg ibuprofen + 50 mg diphenhydramine softgel	Claims 1 and 15, subject to salt, formulation, and use limitations
200 mg ibuprofen tablet plus separate diphenhydramine tablet	Generally outside literal claim scope because there is no single claimed liquid softgel composition
Liquid-filled hard capsule	Potentially outside the literal scope because the claims require a soft gelatin capsule
Softgel without potassium hydroxide	Potentially outside literal scope, subject to claim construction and equivalents

The patent does not require a particular brand, trade name, capsule color, gelatin composition, or manufacturing process.

What do the dependent claims add?

The dependent claims create narrower fallback positions around dosage, salt form, dissolution, and dosing schedule.

Claims	Added limitation
2	Sleep disturbance affects sleep duration
3	Ibuprofen and diphenhydramine are dissolved in the PEG, potassium hydroxide, and water solution
4, 16	Diphenhydramine is HCl or citrate
5	Diphenhydramine HCl is about 12.5-50 mg
6	Diphenhydramine HCl is about 25-50 mg
7, 17	About 25 mg diphenhydramine HCl
8	About 19-38 mg diphenhydramine citrate
9, 18	38 mg diphenhydramine citrate
10	Ibuprofen is about 200-300 mg
11, 19	About 200 mg ibuprofen
12, 21	One dose
13, 22	Two doses
14, 23	One dose and optional second dose

Claims 9, 11, 17, 18, and 19 are commercially significant because they align with standardized OTC doses. A product matching 200 mg ibuprofen and 38 mg diphenhydramine citrate may infringe several claims simultaneously, assuming the product also meets the softgel, solvent, and treatment-purpose limitations.

When does US Patent 8,883,849 lose exclusivity?

The patent issued on November 11, 2014. Its effective expiration depends on the earliest effective nonprovisional filing date in the priority chain, any patent-term adjustment, and any terminal disclaimer. The statutory term is generally 20 years from the earliest effective US nonprovisional filing date under 35 U.S.C. § 154.

The patent front-page term information and USPTO Patent Center record control the operative expiration date. A patent issued in 2014 can remain enforceable after issuance for a shorter or longer period depending on its filing and priority history. Patent expiration should not be inferred solely from the issue date.

The patent does not appear to create biologic-style exclusivity. Its commercial value is limited to the covered OTC combination, dosage form, and method of use.

What is the Orange Book status of US Patent 8,883,849?

The Orange Book question turns on the approved product and NDA holder, not simply on the existence of the patent.

A patent can be relevant to an OTC product without producing a conventional abbreviated new drug application, or ANDA, challenge. OTC products marketed under an FDA monograph generally do not create the same Orange Book patent-listing pathway as prescription NDA products. If the relevant product is marketed under an NDA, the NDA holder may list eligible patents in the Orange Book, subject to FDA listing rules.

US Patent 8,883,849 is a method-of-use patent. A listing analysis would therefore require confirming:

the specific NDA associated with the ibuprofen-diphenhydramine product;
whether the NDA holder listed the patent;
whether the listed use corresponds to the approved labeling;
whether the listing remains active;
whether any delisting, expiration, or correction has occurred.

The Orange Book should be checked by patent number and NDA, rather than by brand name alone. FDA listing status is distinct from enforceability. A listed patent can be challenged, and an unlisted patent can still support litigation outside the statutory ANDA framework. [2]

Which FDA regulatory pathway applies?

Ibuprofen and diphenhydramine are individually established OTC active ingredients. Combination products must comply with the applicable FDA requirements for dosage, labeling, warnings, and permitted indications. FDA’s OTC monograph framework and product-specific approvals are separate regulatory pathways.

The claimed indication, “pain-associated sleep disturbance,” is narrower than a generic “relief of occasional sleeplessness” or “minor aches and pains” statement. The patent’s treatment-method scope depends on how the product is labeled, promoted, prescribed, or used. A generic or OTC competitor may attempt to avoid method-of-use exposure through labeling that omits the patented sleep-related use. That strategy is more difficult if the product is sold with the same combination, dosage form, and consumer messaging.

How strong is the patent estate?

The patent has meaningful formulation and product-mapping strength but limited breadth.

Strengths

The claims target a recognizable commercial dosage form.
The 200 mg ibuprofen dose is expressly claimed.
The 38 mg diphenhydramine citrate dose is expressly claimed.
The 25 mg diphenhydramine HCl dose is expressly claimed.
The softgel limitation can distinguish tablets and conventional capsules.
The claims cover both one-dose and two-dose administration.
The dissolution limitation provides a narrower fallback claim.

Weaknesses

The claims are method claims rather than broad composition claims.
“Pain-associated sleep disturbance” may raise claim-construction and proof issues.
“About” ranges can create boundary disputes.
“Consists of” may exclude formulations containing materially different excipients.
The required potassium hydroxide and water components may provide simple design-around opportunities.
A competitor may use a different dosage form or separate products.
The claims do not expressly cover manufacturing, capsule-shell technology, or every formulation of ibuprofen and diphenhydramine.

The estate is strongest against a directly substitutable liquid-filled softgel that copies the commercial dose and markets the product for nighttime pain relief.

What formulation patents and manufacturing barriers matter?

US Patent 8,883,849 does not monopolize all manufacturing methods for the product. It does not, on its face, claim:

soft gelatin capsule manufacturing;
gelatin cross-linking control;
encapsulation equipment;
polyethylene glycol grades;
ibuprofen particle-size control;
diphenhydramine salt manufacture;
packaging or blister systems;
stability testing methods.

Other patent families could cover those features. A freedom-to-operate review therefore must search the broader family and related portfolios for:

liquid ibuprofen-diphenhydramine compositions;
softgel shell and fill compatibility;
solubilization systems;
capsule sealing;
stability and dissolution;
manufacturing processes;
product labeling and method-of-use claims.

The presence of a design-around formulation does not eliminate manufacturing or regulatory barriers. A competitor still must demonstrate stability, content uniformity, dissolution, capsule integrity, and compliance with FDA labeling requirements.

Are there Paragraph IV challenges or generic litigation?

The supplied claim set does not identify a Paragraph IV certification, ANDA filing, lawsuit, settlement, or court judgment. A reliable litigation conclusion requires a current search of PACER, district-court dockets, FDA Orange Book records, and USPTO assignment and maintenance records.

The likely challenge theories against these claims would include:

anticipation by an earlier ibuprofen-diphenhydramine softgel disclosure;
obviousness based on combining known analgesic and antihistamine products;
lack of written description for the full dosage and salt ranges;
indefiniteness of “about” and “pain-associated sleep disturbance”;
noninfringement based on a different capsule, vehicle, salt, dose, or labeling;
exhaustion or lack of enforceability if the patent term has expired.

A Paragraph IV challenge would be most relevant if a generic applicant sought approval for an NDA-linked product and the patent appeared in the Orange Book. For an OTC-monograph product, the competitive pathway may not use the standard Paragraph IV framework.

Which companies are relevant to the competitive landscape?

The commercial reference product is associated with Pfizer’s Advil consumer-health portfolio. Comparable competitors include products marketed under Motrin PM, store-brand ibuprofen/diphenhydramine labels, and other nighttime analgesic brands. The relevant competitive set includes:

branded ibuprofen-diphenhydramine softgels;
private-label softgels;
ibuprofen tablets combined with diphenhydramine tablets;
acetaminophen-diphenhydramine products;
standalone sleep aids used with analgesics.

A competitor that launches the same 200 mg/38 mg softgel configuration faces greater patent exposure than one using a tablet, a different antihistamine, or separate products. A private-label manufacturer can also face indirect exposure through induced-infringement theories if its labeling or marketing encourages the patented use.

What licensing deals affect this patent?

No publicly disclosed licensing transaction can be attributed to US Patent 8,883,849 based on the claim text alone. Assignment records should be distinguished from licenses. A patent assignment transfers ownership; a license may remain confidential and may not appear in USPTO records.

The commercially important ownership questions are:

original applicant and assignee;
current owner;
recorded security interests;
exclusive licenses;
changes after corporate acquisitions;
maintenance-fee status;
terminal disclaimers or related-family ownership.

What generic launch scenarios exist?

Scenario	Patent and market impact
Same 200 mg/38 mg softgel	Highest infringement and injunction risk if patent remains enforceable
Same actives, tablet dosage form	Lower literal infringement risk; separate formulation and labeling review required
Same softgel, different vehicle	Potential design-around, but equivalents risk remains
200 mg ibuprofen plus 25 mg diphenhydramine HCl	Still maps to multiple claims if all formulation and use limitations are present
Separate ibuprofen and diphenhydramine products	More difficult to establish direct infringement of the single-composition claims
Product labeled only for pain or only for sleep	May reduce method-of-use exposure, but actual marketing and induced-use evidence remain relevant
Post-expiration launch	Patent barrier removed, subject to other patents, regulatory requirements, and market access

Key Takeaways

US Patent 8,883,849 is a method patent covering a liquid ibuprofen-diphenhydramine composition in a soft gelatin capsule.
The core commercial embodiments are 200 mg ibuprofen with either 38 mg diphenhydramine citrate or about 25 mg diphenhydramine HCl.
Claims 1 and 15 are the principal independent claims.
The “consists of” language narrows the composition and creates formulation-based design-around opportunities.
The patent is strongest against a directly substitutable nighttime pain-relief softgel.
Tablets, hard capsules, separate products, and materially different vehicles may avoid literal infringement.
Orange Book relevance depends on the specific NDA and listing history.
The claim text does not establish a Paragraph IV challenge, litigation outcome, or settlement.
Exact patent expiration must be confirmed from the USPTO term record and complete priority chain.

FAQs

Does US Patent 8,883,849 cover Advil PM?

It appears directed to the same commercially relevant type of product: ibuprofen and diphenhydramine in a liquid-filled soft gelatin capsule. Product-specific infringement requires confirming the marketed composition, capsule formulation, labeling, and patent status.

Does a 200 mg ibuprofen and 38 mg diphenhydramine citrate softgel fall within the claims?

It can fall within multiple claims, including claims 1, 8, 9, 15, 16, 18, and 19, if it also contains polyethylene glycol, potassium hydroxide, and water and is administered for pain-associated sleep disturbance.

Can a competitor avoid the patent by using diphenhydramine HCl instead of citrate?

Not necessarily. The claims expressly cover both diphenhydramine hydrochloride and diphenhydramine citrate. A different salt, dose, dosage form, or vehicle may be required for a meaningful design-around.

Does the patent cover a tablet containing ibuprofen and diphenhydramine?

The issued claims require a liquid composition formulated inside a soft gelatin capsule. A conventional tablet generally would not satisfy that limitation.

Is a license required to sell an ibuprofen-diphenhydramine product?

Only if the product practices an enforceable claim or another patent right. A product that avoids this patent may still implicate separate formulation, manufacturing, labeling, or regulatory rights.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,883,849, Treatment of pain-associated sleep disturbance.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
U.S. Food and Drug Administration. (n.d.). Over-the-counter drug monographs.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	309797	⤷ Start Trial
Canada	2434484	⤷ Start Trial
Germany	60207383	⤷ Start Trial
Denmark	1363608	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,883,849

Summary for Patent: 8,883,849